The majority of malaria related deaths worldwide occur in Sub-Saharan Africa, with children under five at greatest risk.
For the 25 million children living across the Sahel, where there is a seasonal surge in malaria incidence, the World Health Organization recommends seasonal malaria chemoprevention (SMC) as an effective tool to prevent malaria.
Malaria Consortium was the to first to trial a seasonal malaria chemoprevention (SMC) intervention in 2013, rolling out a pilot project in Katsina state, Nigeria. Following encouraging results, Malaria Consortium and partners were awarded a UNITAID grant to collaborate with National Malaria Control programmes to lead the first-ever at-scale roll out of seasonal malaria chemoprevention (SMC) across seven countries in the Sahel region: Burkina Faso, Chad, Guinea Conakry, Mali, Niger, Nigeria and The Gambia. Achieving Catalytic Expansion of Seasonal Malaria Chemoprevention in the Sahel (ACCESS-SMC) will provide 45 million preventive treatments over the next two years, helping to protect over 10 million children from malaria.
